clinical trial · NCT00835614
Cefprozil for Oral Suspension 250 mg/5 mL, Fasting
Teva Pharmaceuticals USA·phase1·completed·n = 26
HealthyCefprozil for oral suspension 250 mg/5 mLCEFZIL® for Oral Suspension 250 mg/5mL
brief summary
The objective of this study is to compare the relative bioavailability of cefprozil for oral suspension 250 mg/5 mL (TEVA Pharmaceuticals USA) with that of CEFZIL® for Oral Suspension 250 mg/5 mL (Bristol-Myers Squibb) in healthy, non-smoking adults under fasting conditions.
started
Apr 1, 2004
primary completion
Apr 1, 2004
completion
Apr 1, 2004
last updated
Aug 20, 2024
detailed description
Criteria for Evaluation: FDA Bioequivalence Criteria
Statistical Methods: FDA bioequivalence statistical methods
official title
A Relative Bioavailability Study of Cefprozil for Oral Suspension 250 mg/5 mL Under Fasting Conditions
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol